Pfizer Inc. said on Thursday it would buy privately-held ReViral Ltd. in a deal worth as much as $525 million including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus (RSV). The deal marks the U.S. drugmaker’s second acquisition in less than six months to boost its drug portfolio, after a…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`